{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:34:49Z","timestamp":1791646489916,"version":"4.3.4"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic inflammation is an essential pathophysiological factor of heart failure with preserved ejection fraction (HFpEF) that supports the use of statins. The purpose of the study was to determine the effects of statin therapy with atorvastatin or rosuvastatin on functional capacity, cardiac remodeling, profibrotic and inflammatory biomarkers in patients with HFpEF. Since lipophilic and hydrophilic statins may exert different effects on HF, we also compared the effects of lipophilic atorvastatin vs. hydrophilic rosuvastatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We enrolled 59 patients with HFpEF who had no history of statin use or had not received statins for 6 months. Participants were randomly assigned to receive atorvastatin (20\u201380\u2005mg a day,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200930) or rosuvastatin (10\u201340\u2005mg a day,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200929) for 6 months. Echocardiography, 6\u2005min walk distance (6MWTD), biomarkers of inflammation (hsCRP and MCP-1), and extracellular matrix homeostasis (PICP and sST2) were analyzed at baseline and after 6 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 6 months of therapy, atorvastatin was associated with a greater increase in 6MWTD than rosuvastatin, but both statin groups showed comparable improvements in NYHA functional class and bicycle exercise duration. There were comparable decreases in E\/e\u2032 ratio and left atrial (LA) volume index, as well as comparable improvements in diastolic (e\u2032 velocity enhancement on exercise) and chronotropic (heart rate enhancement on exercise) reserves in both statin groups. Atorvastatin was superior to rosuvastatin in modifying LA reserve (reservoir strain enhancement on exercise). A significant decrease in blood levels of all biomarkers was observed in the atorvastatin group but not in the rosuvastatin group. Rosuvastatin was associated with a reduction in hsCRP and MCP-1 only in subgroups of patients with baseline values above the median.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In HFpEF, statin therapy appears to be associated with improved functional capacity, possibly by reducing LV filling pressure and favoring cardiac remodeling. Atorvastatin may provide some additional benefits compared with rosuvastatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/rosrid.ru<\/jats:ext-link>\n                      , identifier AAAA-A18-118022290061-2.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1870027","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:17:37Z","timestamp":1783923457000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of statins on functional capacity and cardiac remodeling in patients with heart failure and preserved ejection fraction: a randomized open-label pilot trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Artem","family":"Ovchinnikov","sequence":"first","affiliation":[{"name":"Laboratory of Myocardial Fibrosis and Heart Failure with Preserved Ejection Fraction, National Medical Research Center of Cardiology Named After Academician E. I. Chazov","place":["Moscow, Russia"]},{"name":"Department of Clinical Functional Diagnostics, Russian University of Medicine of the Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Potekhina","sequence":"additional","affiliation":[{"name":"Laboratory of Myocardial Fibrosis and Heart Failure with Preserved Ejection Fraction, National Medical Research Center of Cardiology Named After Academician E. I. Chazov","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Svirida","sequence":"additional","affiliation":[{"name":"Laboratory of Myocardial Fibrosis and Heart Failure with Preserved Ejection Fraction, National Medical Research Center of Cardiology Named After Academician E. I. Chazov","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Arefieva","sequence":"additional","affiliation":[{"name":"Laboratory of Cell Immunology, National Medical Research Center of Cardiology Named After Academician E. I. Chazov","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamila","family":"Martynyuk","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Hypertension and Heart Disease, National Medical Research Center of Cardiology Named After Academician E. I. Chazov","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fail","family":"Ageev","sequence":"additional","affiliation":[{"name":"Out-Patient Department, National Medical Research Center of Cardiology Named After Academician E. I. Chazov","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijana","family":"Tadic","sequence":"additional","affiliation":[{"name":"University Heart Center Ulm, University Ulm","place":["Ulm, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Belyavskiy","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum der Charit\u00e9, Medizinisches Versorgungszentrum","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Hamo","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1152\/japplphysiol.00775.2023","article-title":"Statin administration improves vascular function in heart failure with preserved ejection fraction","volume":"136","author":"Iacovelli","year":"2024","journal-title":"J Appl Physiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"H859","DOI":"10.1152\/ajpheart.00427.2024","article-title":"Statin therapy improves locomotor muscle microvascular reactivity in patients with heart failure with preserved ejection fraction","volume":"327","author":"Iacovelli","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.arcmed.2010.08.009","article-title":"Effects of statin therapy on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials","volume":"41","author":"Zhang","year":"2010","journal-title":"Arch Med Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1097\/HJH.0000000000000184","article-title":"Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats","volume":"32","author":"Akahori","year":"2014","journal-title":"J Hypertens"},{"key":"B8","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/eurjhf\/hfq101","article-title":"Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction","volume":"12","author":"G\u00f3mez-Garre","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/s0735-1097(02)01717-5","article-title":"Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension","volume":"39","author":"Ferrier","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jacc.2007.10.009","article-title":"Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy","volume":"51","author":"Ramasubbu","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.113.001475","article-title":"Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study","volume":"128","author":"Zakeri","year":"2013","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2169\/internalmedicine.46.0021","article-title":"Impact of statin therapy on systemic inflammation, left ventricular systolic and diastolic function and prognosis in low risk ischemic heart disease patients without history of congestive heart failure","volume":"46","author":"Okura","year":"2007","journal-title":"Intern Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.amjcard.2011.01.054","article-title":"Effect of low-dose (1\u2005mg\/day) pitavastatin on left ventricular diastolic function and albuminuria in patients with hyperlipidemia","volume":"107","author":"Yagi","year":"2011","journal-title":"Am J Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.3390\/jcm11133885","article-title":"Asymptomatic left ventricular hypertrophy is a potent risk factor for the development of HFpEF but not HFrEF: results of a retrospective cohort study","volume":"11","author":"Ovchinnikov","year":"2022","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1161\/CIRCHEARTFAILURE.115.002143","article-title":"Association between use of statins and mortality in patients with heart failure and ejection fraction of \u226550","volume":"8","author":"Alehagen","year":"2015","journal-title":"Circ Heart Fail"},{"key":"B16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.amjcard.2018.04.027","article-title":"Comparison of effects of statin use on mortality in patients with heart failure and preserved versus reduced left ventricular ejection fraction","volume":"122","author":"Lee","year":"2018","journal-title":"Am J Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1253\/circj.CJ-14-0865","article-title":"Prognostic impact of statin use in patients with heart failure and preserved ejection fraction","volume":"79","author":"Nochioka","year":"2015","journal-title":"Circ J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.amjcard.2013.12.023","article-title":"Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction","volume":"113","author":"Liu","year":"2014","journal-title":"Am J Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12944-019-1135-z","article-title":"Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis","volume":"18","author":"Bielecka-Dabrowa","year":"2019","journal-title":"Lipids Health Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ijcard.2016.03.186","article-title":"The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses","volume":"214","author":"Fukuta","year":"2016","journal-title":"Int J Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/1755-5922.12150","article-title":"Effects of statin treatment on inflammation and cardiac function in heart failure: an adjusted indirect comparison meta-analysis of randomized trials","volume":"33","author":"Bonsu","year":"2015","journal-title":"Cardiovasc Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/ehjci\/jey042","article-title":"Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI\/ASE\/industry task force to standardize deformation imaging","volume":"19","author":"Badano","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ejhf.1488","article-title":"Empagli\ufb02ozin improves functional capacity and LV diastolic function in patients with HFpEF and type-2 diabetes mellitus: preliminary results of randomized open-label trial","volume":"22","author":"Borisov","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B27","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.111.076075","article-title":"Low myocardial protein kinase G activity in heart failure with preserved ejection fraction","volume":"126","author":"van Heerebeek","year":"2012","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/CIRCULATIONAHA.110.985150","article-title":"Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling","volume":"124","author":"Antoniades","year":"2011","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.104.519876","article-title":"Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report","volume":"112","author":"Fukuta","year":"2005","journal-title":"Circulation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1253\/circj.CJ-18-0639","article-title":"Effect of statins on mortality in heart failure with preserved ejection fraction without coronary artery disease\u2014report from the JASPER study","volume":"83","author":"Marume","year":"2019","journal-title":"Circ J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jacc.2010.03.077","article-title":"Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction","volume":"56","author":"Borlaug","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1093\/eurheartj\/ehu193","article-title":"Right heart dysfunction in heart failure with preserved ejection fraction","volume":"35","author":"Melenovsky","year":"2014","journal-title":"Eur Heart J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijcard.2017.04.103","article-title":"Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome","volume":"240","author":"Yamada","year":"2017","journal-title":"Int J Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.atherosclerosis.2011.02.036","article-title":"Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect","volume":"216","author":"Mannheim","year":"2011","journal-title":"Atherosclerosis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1161\/01.cir.0000029743.68247.31","article-title":"Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction","volume":"106","author":"Plenge","year":"2002","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.biopha.2016.06.034","article-title":"Amlodipine and atorvastatin improve ventricular hypertrophy and diastolic function via inhibiting TNF-alpha, IL-1beta and NF-kappaB inflammatory cytokine networks in elderly spontaneously hypertensive rats","volume":"83","author":"Lu","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"B37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1161\/hc2801.094031","article-title":"Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy","volume":"104","author":"Patel","year":"2001","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10741-020-09927-x","article-title":"Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"26","author":"Lakhani","year":"2021","journal-title":"Heart Fail Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1064967","DOI":"10.3389\/fcvm.2022.1064967","article-title":"C-reactive protein and statins in heart failure with reduced and preserved ejection fraction","volume":"9","author":"Park","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1248\/bpb.b15-00126","article-title":"Effects of statins on left ventricular diastolic function in patients with dyslipidemia and diastolic dysfunction (stat-LVDF study)","volume":"38","author":"Morimoto","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.amjcard.2009.07.055","article-title":"Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure","volume":"104","author":"Lipinski","year":"2009","journal-title":"Am J Cardiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/ehjcvp\/pvz079","article-title":"An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC working group on cardiovascular pharmacotherapy: barriers to be overcome","volume":"6","author":"Drexel","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/ejhf.2064","article-title":"Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-preserved trial","volume":"22","author":"Anker","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B47","doi-asserted-by":"publisher","first-page":"701","DOI":"10.7326\/M24-0004","article-title":"Benefits and risks associated with statin therapy for primary prevention in old and very old adults: real-world evidence from a target trial emulation study","volume":"177","author":"Xu","year":"2024","journal-title":"Ann Intern Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"100869","DOI":"10.1016\/j.jacadv.2024.100869","article-title":"Initiation of statins for primary prevention in heart failure with preserved ejection fraction","volume":"3","author":"Orkaby","year":"2024","journal-title":"JACC Adv"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1161\/CIRCHEARTFAILURE.115.002249","article-title":"Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"8","author":"Shah","year":"2015","journal-title":"Circ Heart Fail"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1870027\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:17:38Z","timestamp":1783923458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1870027\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":49,"alternative-id":["10.3389\/fcvm.2026.1870027"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1870027","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"article-number":"1870027"}}